Steminent Biotherapeutics Inc. is a clinical-stage biopharmaceutical company developing and commercializing innovative and proprietary adipose tissue-derived cellular therapeutics for treating patients with medical conditions for which there are no effective treatments or where the quality of current treatment can be improved.

The Company is developing its Stemchymal® proprietary stem cell product platform for multiple disease indications, focusing initially on leading therapeutic candidates for neurodegenerative diseases and osteoarthritis of the knee. The leading Stemchymal® PolyQ SCA program had completed a PI/II trial in spinocerebellar ataxia in 2014 and is conducting a Phase II study.

Steminent has entered into collaborations with academic, clinical, industry, and regulatory partnerships in North America, Japan, and Europe to further develop Stemchymal® platform and advance products which meet global standards.